Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-800-3636
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.73 million
Profitability
Miscellaneous
Employees206
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable
Achaogen (NASDAQ:AKAO) Frequently Asked Questions
What is Achaogen's stock symbol?
Achaogen trades on the NASDAQ under the ticker symbol "AKAO."
How were Achaogen's earnings last quarter?
Achaogen Inc (NASDAQ:AKAO) announced its quarterly earnings results on Monday, August, 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to analyst estimates of $1.49 million. Achaogen had a negative net margin of 2,136.94% and a negative return on equity of 357.49%. View Achaogen's Earnings History.
When is Achaogen's next earnings date?
What price target have analysts set for AKAO?
9 brokerages have issued 1-year price objectives for Achaogen's shares. Their predictions range from $2.00 to $22.00. On average, they anticipate Achaogen's share price to reach $10.00 in the next year. This suggests a possible upside of 6,566.7% from the stock's current price. View Analyst Price Targets for Achaogen.
What is the consensus analysts' recommendation for Achaogen?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achaogen in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achaogen.
What are Wall Street analysts saying about Achaogen stock?
Here are some recent quotes from research analysts about Achaogen stock:
- 1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (4/16/2019)
- 2. Needham & Company LLC analysts commented, "Achaogen hosted a 4Q18 conference call yesterday to provide a corporate update. Zemdri sales were $0.5M, consistent w/ pre-announced $0.45-0.5M. Mgmt implemented another corporate restructure in Feb 2019 to conserve resources. Sales force and MSL group has been scaled back to only a few personnel who will focus on a modest number of existing accounts. The move is expected to reduce cash burn to $15-17M in 2Q19, pushing runway to Jun 2019. Mgmt continues to examine strategic options, although no details provided. Zemdri is still used primarily in outpatient setting. Given small commercial infrastructure, it seems unlikely the drug will meaningfully penetrate the inpatient hospital setting even as hospitals gradually add the drug to formulary." (3/29/2019)
- 3. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value Rating ZEMDRI – U.S. 100% $1.35 $1.35 Shares outstanding 63,206 S/O: Post-Feb 2019 equity raise. ZEMDRI – EU 35% $0.35 $1.00 Current share price $0.86 Discount rate 24.0% C-Scape – U.S." (2/21/2019)
- 4. Mizuho analysts commented, "We see significant risk in Achaogen even though we believe ZEMDRI is a positively differentiated product with strategic value. We reduce our 2019 revenue from ~ $27mn to ~$14mn; reiterate Neutral and $3 PT." (2/15/2019)
Has Achaogen been receiving favorable news coverage?
News coverage about AKAO stock has trended somewhat positive on Monday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Achaogen earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near term.
Who are some of Achaogen's key competitors?
Some companies that are related to Achaogen include ContraFect (CFRX), KemPharm (KMPH), Aerpio Pharmaceuticals (ARPO), Novus Therapeutics (NVUS), BIOLINERX LTD/S (BLRX), VIVUS (VVUS), Moleculin Biotech (MBRX), Heat Biologics (HTBX), OncoSec Medical (ONCS), Oncomed Pharmaceuticals (OMED), ProPhase Labs (PRPH), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Leap Therapeutics (LPTX), Aptevo Therapeutics (APVO) and Oncolytics Biotech (ONCY).
What other stocks do shareholders of Achaogen own?
Who are Achaogen's key executives?
Achaogen's management team includes the folowing people:
- Mr. Blake Wise, CEO & Director (Age 48)
- Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 49)
- Ms. Zeryn Sarpangal, CFO and Principal Financial & Accounting Officer (Age 39)
- Ms. Elizabeth Bhatt, Chief Bus. Officer & COO (Age 50)
- Ms. Jeannie Lloyds, VP of Sales
Who are Achaogen's major shareholders?
Achaogen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.09%). Company insiders that own Achaogen stock include Blake Wise, Elizabeth Bhatt, Gary Loeb, Janet Dorling, Kenneth J Hillan, Robert W Duggan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.
Which major investors are buying Achaogen stock?
How do I buy shares of Achaogen?
Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achaogen's stock price today?
One share of AKAO stock can currently be purchased for approximately $0.15.
How big of a company is Achaogen?
Achaogen has a market capitalization of $9.58 million and generates $8.73 million in revenue each year. The biopharmaceutical company earns $-186,510,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Achaogen employs 206 workers across the globe.
What is Achaogen's official website?
How can I contact Achaogen?
Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]
MarketBeat Community Rating for Achaogen (NASDAQ AKAO)
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.
